Lost Money on Alector, Inc. (ALEC)? Contact Levi & Korsinsky About Investigation

New York, New York--(Newsfile Corp. - October 22, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Alector, Inc. ("Alector, Inc.") (NASDAQ: ALEC) concerning possible violations of federal securities laws.

On October 22, 2025, Alector announced results from its Phase 2 INFRONT-3 clinical trial evaluating latozinemab (AL001) in patients with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The company reported that "latozinemab did not demonstrate a clinical benefit" for slowing FTD-GRN progression in its 96-week double-blind trial.

Following this news, ALEC's stock price fell over 52% to open at $1.54 per share. To obtain additional information, go to:

https://zlk.com/pslra-1/alector-inc-lawsuit-submission-form?prid=173497&wire=5&utm_campaign=48

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271509